A. Teitelbaum

发表

Health care costs for patients with cancer at the end of life.

J. Kallich, L. Newcomer, C. Paoli, 2012, Journal of oncology practice.

Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study

B. Seal, Lisa Le, A. Aly, 2021, Cancer reports.

Original article Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases

H. Henk, S. Kaura, A. Teitelbaum, 2012 .

Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases

H. Henk, S. Kaura, A. Teitelbaum, 2012, Journal of medical economics.

Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma

H. Henk, S. Kaura, A. Teitelbaum, 2012, American journal of hematology.

Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry

O. Baser, H. Henk, Wenhui Wei, 2012, Current medical research and opinion.

Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

H. Henk, S. Kaura, A. Teitelbaum, 2012, Current medical research and opinion.

Small noncleaved follicular center cell (FCC) lymphoma: Burkitt and non‐Burkitt variants in the United States. I. Clinical features

A. Paganini-Hill, J. Parker, R. Lukes, 1983, Cancer.

Antithrombin III and anti‐activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin

A. Levine, H. Liebman, D. Feinstein, 1982, Cancer.

Distribution of T-cell phenotypic subsets and surface immunoglobulin-bearing lymphocytes in lymph nodes from male homosexuals with persistent generalized adenopathy: an immunohistochemical and ultrastructural study.

J. Said, I. Shintaku, A. Teitelbaum, 1984, Human pathology.

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

H. Henk, A. Teitelbaum, Hui Huang, 2013, The oncologist.

Eye Symptoms and Toxicities of Systemic Chemotherapy

A. Teitelbaum, 2010 .

157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer

A. Teitelbaum, A. Gordon, 2003 .

Filgrastim (r-metHuG-CSF) reversal of drug-induced agranulocytosis.

A. Teitelbaum, S. Brown, A. Bell, 1993, The American journal of medicine.

Clinical a nd I mmune R esponses i n A dvanced M elanoma Patients I mmunized W ith a n A nti-Idiotype A ntibody Mimicking D isialogangliosi de G D2

K. Foon, L. Hutchins, R. Reisfeld, 2000 .

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

K. Foon, L. Hutchins, R. Reisfeld, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs

C. Reyes, A. Teitelbaum, R. Linke, 2013, Melanoma research.

Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population

D. Mytelka, L. Bowman, A. Teitelbaum, 2013, Journal of medical economics.

Original article Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population

D. Mytelka, L. Bowman, S. Byfield, 2013 .

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population

L. Menditto, A. Haiderali, M. Good, 2011, Supportive Care in Cancer.

Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma.

A. Teitelbaum, M. Acosta, 2001, Journal of the American Academy of Dermatology.

Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer

S. Ray, A. Teitelbaum, V. Bonthapally, 2013, Journal of Neuro-Oncology.

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.

K. Foon, W. John, O. Kashala, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes

N. Engel-Nitz, E. Hulbert, A. Teitelbaum, 2014, BMC Clinical Pathology.

Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab

L. Becker, A. Teitelbaum, A. Parthan, 2014, Journal of managed care & specialty pharmacy.

Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer

D. Reece, G. Phillips, M. Bhattacharya‐Chatterjee, 2000, Bone Marrow Transplantation.

P1-08-07: Survival in US Women Following an Indication of Metastatic Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-Medicare Analysis.

H. Rugo, K. Clements, Douglas C. A. Taylor, 2011 .

An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data

Joel D Kallich, J. Whyte, J. Kallich, 2015, Medical care.

Burden of Early-Stage Triple-Negative Breast Cancer in a US Managed Care Plan

O. Baser, H. Henk, Wenhui Wei, 2012 .

Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population

Á. Benedict, H. Henk, Connie Chen, 2013, ClinicoEconomics and outcomes research : CEOR.

Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database

T. Bell, T. Burton, S. Byfield, 2016, Current medical research and opinion.

Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population

M. Amonkar, B. Chastek, A. Teitelbaum, 2011, Journal of medical economics.

Clinical a nd I mmune R esponses i n R esected C olon C ancer Patients T reated W ith A nti-Idiotype M onoclonal A ntibody Vaccine T hat M imics t he C arcinoembryonic A ntigen

K. Foon, W. John, O. Kashala, 1999 .

Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents

R. Morlock, A. Teitelbaum, E. Yu, 2013, Journal of medical economics.

PSY19 MULTIPLE MYELOMA: PATIENT OUT-OF-POCKET COSTS AND HEALTH-CARE UTILIZATION

B. Pinsky, A. Teitelbaum, Hui Huang, 2010 .

Multiple Myeloma: Patient out-of-Pocket Costs and Health Care Utilization.

D. Esseltine, H. Henk, B. Pinsky, 2009 .